Yahoo · Oct 17, 2026
Amgen's Q3 2026 Earnings: What to Expect
Amgen is scheduled to report its third-quarter results next month, and analysts expect a single-digit earnings rise.
AM
NYSE · AMGN
Amgen Inc.
Healthcare · Drug Manufacturers - General
$432.49
Down-$1.54 (-0.35%)
Updated Oct 19, 2026, 8:15 AM
SID Score
7.4/10
Composite research score
Smart Money
51/100
Neutral
- Market cap
- 209.24B
- P/E ratio
- 27.13
- Dividend yield
- 2.78%
- 52-week range
- $318.21 – $447.03
- Volume
- 2.57M
- Avg. volume
- 2.89M
Price performance · AMGN
AMGN price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 16, 2026
AMGN closed at $432.49 after 20 trading sessions, up 10.00% for the selected period.
- Last close
- $432.49
- Period change
- +10.00%
- Period low
- $393.16
- Period high
- $434.03
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | $437.89 | $438.82 | $431.39 | $432.49 | 2.57M |
| Oct 15, 2026 | $435.83 | $441.7599 | $433.42 | $434.03 | 4.63M |
| Oct 14, 2026 | $417.83 | $428.05 | $415.1951 | $426.11 | 3.09M |
| Oct 13, 2026 | $420.34 | $420.35 | $411.04 | $412.84 | 2.32M |
| Oct 12, 2026 | $416.12 | $417.76 | $413.44 | $417.57 | 1.72M |
| Oct 9, 2026 | $405.00 | $417.78 | $404.05 | $414.87 | 2.55M |
| Oct 8, 2026 | $409.97 | $411.84 | $400.06 | $407.44 | 2.38M |
| Oct 7, 2026 | $403.06 | $415.79 | $401.85 | $413.08 | 2.24M |
| Oct 6, 2026 | $403.30 | $405.00 | $396.01 | $402.60 | 2.04M |
| Oct 5, 2026 | $399.03 | $403.69 | $397.03 | $402.98 | 3.1M |
| Oct 2, 2026 | $410.16 | $410.16 | $401.96 | $403.04 | 3.51M |
| Oct 1, 2026 | $421.72 | $422.80 | $407.13 | $407.27 | 2.5M |
| Sep 30, 2026 | $424.01 | $426.59 | $420.63 | $421.51 | 3.13M |
| Sep 29, 2026 | $414.37 | $424.57 | $414.11 | $423.64 | 3.74M |
| Sep 28, 2026 | $411.52 | $419.02 | $410.955 | $418.13 | 2.92M |
| Sep 25, 2026 | $408.25 | $415.20 | $404.19 | $414.61 | 2.21M |
| Sep 24, 2026 | $406.09 | $409.99 | $403.88 | $406.04 | 2.53M |
| Sep 23, 2026 | $410.09 | $415.76 | $404.34 | $406.09 | 2.82M |
| Sep 22, 2026 | $405.25 | $412.995 | $398.52 | $410.24 | 3.72M |
| Sep 21, 2026 | $385.71 | $394.50 | $381.90 | $393.16 | 2.89M |
Latest AMGN news
The latest Smart Investors Daily articles mentioning AMGN.
Stock researchCompany · Overview
Company
Market Activity
Research & News
AMGN research
Overview
Company profile and research snapshot.
Company profile
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Hold
- Average target
- $368.50
- Implied upside
- —
- Analysts
- 21
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 13, 2026 | Guggenheim | Neutral | — |
| Oct 12, 2026 | Wells Fargo | Equal-Weight | — |
| Oct 12, 2026 | BMO Capital | Market Perform | — |
| Oct 9, 2026 | UBS | Buy | — |
| Oct 8, 2026 | RBC Capital | Outperform | — |
News briefing
Generated Oct 18, 2026, 9:04 PM
Why Is AMGN Down Today?
Amgen shares declined 0.35% today in modest trading activity, with no major breaking news driving the movement. Instead, the biotech giant is in a holding pattern as investors await Q3 2026 earnings results and digest the company's long-term value proposition ahead of potential catalyst events.
Bottom line: Amgen's modest 0.35% decline appears driven by pre-earnings positioning rather than fundamental deterioration, with the stock maintaining its status as a stable biotech holding despite near-term competitive headwinds from peers like Biogen. Investors should monitor Q3 2026 results closely for pipeline updates and guidance revisions that could catalyze meaningful price movement, while the company's long-term dividend and cash generation story remains intact.
Benzinga · Oct 16, 2026
Here's How Much $100 Invested In Amgen 15 Years Ago Would Be Worth Today
Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 1.45% on an annualized basis producing an average annual return of 14.3%. Currently, Amgen has a market capitalization of $230.37 billion.
SeekingAlpha · Oct 16, 2026
Biogen: The Bull Case Is Extending Beyond Alzheimer's (Rating Upgrade)
Biogen's Q3 earnings are due Oct 28. Explore FY2026 EPS guidance, Alzheimerâs revenue growth, and key risk/reward driversâread now. Click for this BIIB update.
Yahoo · Oct 15, 2026
Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider
The latest trading day saw Amgen (AMGN) settling at $434.03, representing a +1.86% change from its previous close.
AI research layers
Interpretive context generated from the platform’s current data sources.
Amgen Inc. Stock Performance
Amgen Inc. shares closed at $432.49, reflecting a single-session decline of 2.50% per SID market data. Despite the recent pullback, the stock has demonstrated sustained upward momentum across multiple timeframes, gaining 13.88% over the past month and 18.76% over the trailing three months. On a twelve-month basis, AMGN has appreciated 31.2%, significantly outperforming many large-cap healthcare peers. The stock currently trades above both its 50-day moving average of $415.01 and its 200-day moving average of $373.56, according to Massive/Polygon technical indicators, confirming the longer-term bullish trend structure. The 14-day relative strength index stands at 58.9, positioning the stock in neutral territory without signaling overbought or oversold conditions. AMGN's beta of 0.472 reflects substantially lower volatility relative to the broader market. Average daily trading volume registers at approximately 2.89 million shares, supporting consistent institutional liquidity.
Amgen Inc. Valuation Analysis
Amgen Inc. carries a market capitalization of approximately $209.2 billion, placing it among the largest biotechnology companies globally, per SID market data. The stock trades at a price-to-earnings ratio of 27.13, which is elevated relative to the broader healthcare sector's historical median, reflecting investor expectations for sustained revenue growth from its expanding product portfolio. The PEG ratio stands at 2.72, suggesting the current earnings multiple is not fully supported by projected growth rates according to consensus estimates. Amgen's price-to-book ratio of 24.16 remains notably high, consistent with the capital-light, intangible-asset-heavy nature of biopharmaceutical businesses. According to SEC filings, the company maintains a forward dividend yield of approximately 2.49%, providing meaningful income for shareholders. This yield positions AMGN as one of the higher-yielding large-cap biotech names, balancing growth exposure with capital return considerations for income-oriented investors in the healthcare space.
Smart Money Activity for AMGN
Amgen Inc. registers a composite smart money score of 51 out of 100, reflecting a neutral overall signal per SID market data. Institutional positioning represents the strongest component at a perfect 25 out of 25, indicating robust ownership and continued accumulation by major fund managers as documented in 13F institutional filings. In contrast, the insider activity score stands at 8.6 out of 25, with SEC Form 4 filings revealing 15 insider transactions over the past 90 days, comprising 9 purchases and 6 sales. The net buying bias among corporate insiders suggests measured confidence in the company's trajectory, though the overall insider score remains modest. Dark pool activity scores 8.5 out of 25, indicating limited notable block trading patterns in off-exchange venues. Congressional trading activity registers at 8.8 out of 25, showing moderate engagement from elected officials. The divergence between strong institutional conviction and subdued insider and dark pool signals contributes to the overall neutral composite reading for AMGN.
Amgen Inc. Earnings Outlook
Amgen Inc. has delivered consecutive positive earnings surprises across its three most recent reporting periods, according to company earnings reports. In Q4, the company posted earnings per share of $5.29 against a consensus estimate of $4.75, representing a $0.54 upside surprise. The Q3 period saw EPS of $5.15 versus the $4.76 estimate, a $0.39 beat, while Q2 results came in at $6.29 compared to the $5.60 consensus, delivering the largest surprise at $0.69 per share. This consistent pattern of outperformance suggests conservative guidance practices or stronger-than-modeled operational execution. Looking ahead, analysts estimate Q1 earnings of $5.75 per share, with results expected on November 3, per analyst estimates. The sequential trajectory across quarters indicates stable profitability, with the Q2 figure of $6.29 marking the peak among recent periods. Investors will monitor whether Amgen can sustain its beat trend in the upcoming report.
Wall Street Analyst Ratings for AMGN
Wall Street consensus on Amgen Inc. reflects a divided outlook, with recent analyst activity split between neutral and constructive stances, per SID consensus data. In October 2026, Guggenheim reiterated a Neutral rating, while Wells Fargo maintained its Equal-Weight position and BMO Capital held at Market Perform, collectively reflecting a cautious view among several prominent firms. Conversely, UBS reiterated its Buy rating on October 9, and RBC Capital maintained an Outperform recommendation on October 8, according to Wall Street analyst reports. The clustering of five ratings actions within a single week suggests the coverage updates were likely prompted by a material company event or sector catalyst. Notably, none of the five analysts changed their prior recommendations, indicating stable conviction levels across the coverage universe. The 3-to-2 split favoring neutral over bullish ratings aligns with valuation concerns reflected in the elevated PEG ratio of 2.72, while bullish analysts appear focused on Amgen's pipeline catalysts and revenue diversification potential.
